AstraZeneca heads into its October 30 results with the most newsworthy development of the week sitting in the insider register, not the lending market.
Chief Executive Pascal Soriot bought 60,000 shares on September 14 at 121.02p, a purchase worth roughly £7.3 million. Non-Executive Chair Michel Demaré added 2,500 shares at the same time. Both are open-market purchases, made at a price below where the stock closed this week, and both represent a deliberate bet on the company ahead of a quarterly print. The CFO received small share grants around the same date, but those are compensation mechanics and carry no directional signal. Net, insiders added 62,500 shares over the past 90 days, all of it Soriot and Demaré buying.
The lending market tells a completely different story: there is no short pressure here whatsoever. Borrow availability is essentially uncapped, with more than 1.1 billion shares available to lend against minimal demand. The cost to borrow has also fallen sharply, dropping more than 50% over the past week to 0.25%, its lowest level in the 30-day window. Shorts represent a rounding error, and the ORTEX short score of 25.6 ranks in the 96th percentile for low short pressure across the universe. This is a stock where bears have shown no meaningful interest, and the borrow market reflects that with unusual clarity.
The Street picture is harder to read cleanly. Available analyst data on AZN is more than three years old and should not be treated as current. What the ORTEX factor scores do show is a company scoring well on dividend (89th percentile), EPS momentum over 30 days (84th percentile), and days-to-cover (77th percentile). The PE multiple has expanded about 0.4 points over the past month to 14.7x, while EV/EBITDA has drifted slightly lower to 11.7x. Forward earnings revisions have been strong: an earlier stock-score note flagged a 152% year-on-year increase in forward EPS, which is the main driver of AZN's 86-point composite score. The stock closed at 124.28p on Tuesday, off about 1.9% on the week, broadly in line with the pharma peer group. GSK fell 2.6% over the same period, while Novartis bucked the trend, gaining 3.8%.
AZN's own clinical-trial register, tracked daily by the US National Library of Medicine, has not been measured as a leading indicator of the company's reported figures, so it provides context on pipeline activity but no read-through to the October print.
With earnings 30 days out, the question worth tracking is whether Soriot's purchase at 121p holds as a floor, or whether the week-on-week softness in the share price extends into the results period.
See the live data behind this article on ORTEX.
Open AZN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
